PROFILE: Chi-Med Lays Out Broad Strategy As Fruquintinib Advances
This article was originally published in PharmAsia News
Executive Summary
Newly NASDAQ-listed Chi-Med has completed enrollment in a Phase III trial with fruquintinib in colorectal cancer patients in China, a potentially large market for its lead drug, and is pushing ahead with US development plans for the VEGFR inhibitor. The Hong Kong-based firm also sees attractive possibilities for combination use in earlier lines of therapy and in additional indications and mature markets, its CEO says.
You may also be interested in...
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.